As a pioneer in the bispecific antibody (BsAbs) development and manufacture, Creative Biolabs offers many different formats of BsAbs. Based on our vast experience gained from developing hundreds of antibodies, we offer antibody-peptide conjugates with high affinity and low immunogenicity for both academic and clinical purposes.
In bispecific molecules, the functional portions targeting antigens include not only antibodies but also some small drugs or peptides. In BsAb repertoire, antibody-peptide conjugates, also referred to as chemically programmed antibodies (cpAbs), are a novel class of pharmaceuticals utilizing small molecules as the navigator instead of mAb.
As therapeutic agents, mAbs and peptides have their merits. Over the past two decades, mAbs have become high successful pharmaceuticals. A large number of mAbs have been approved by FDA or/and EMA and some are in phase III clinical trials. The reasons behind the boom of mAbs include their high affinity and specificity for antigens, their large size enabling the prolonged half-life and the Fc-mediated effector functions of mAbs with Fc portion. By contrast, peptides also have high affinity with unlimited access to almost all niches of cells, meanwhile they are easier to manufacture. Antibody-peptides conjugates combine the advantages of mAbs and small molecules.
The antigen binding of conventional mAbs relies on the virtue of six CDRs. While in chemically programmed antibodies, peptides are responsible for the antigen binding, which is site-specifically and can covalently linked to the antibody scaffold by the approach of “chemical programming”. The antibody scaffold equips the peptides with the long half-life, Fc-mediated effector functions and bivalence of conventional mAbs. Moreover, the scaffold antibody augments the ability to interfere with ligand-receptor interactions. To construct an intact antibody-peptide conjugates, four elements are needed: a scaffold antibody, a peptide pharmacophore, a reactive group and a linker spacing pharmacophore and reactive group. The scaffold antibody may be IgGs or fragments. And the pharmacophores can also be peptidomimetics, DNA/RNA aptamer or other small molecules. The conjugation of the pharmacophores with the scaffold antibody requires unique reactivity centers. Up to now, there are mainly three reactivity centers: engineered C-terminal selenocysteine (U), N-terminal cysteine (C) residues and lysine (K) residue in the paratope (Fig. 1)
Figure 1. The conventional IgG and antibody-peptide conjugate: the blue modules are pharmacophore and the red modules are reactive groups. (Christoph, R., 2014)
With our well-established bispecific antibody generation and conjugation platforms, the experienced scientists here at Creative Biolabs are dedicated to help you develop unique antibody-peptide conjugates. We also provide other various services regarding BsAbs development. Please feel free to contact us for more information and a detailed quote.
1. Doppalapudi, V. R.; et al. Chemical generation of bispecific antibodies. Proceedings of the National Academy of Sciences. 2010, 107(52): 22611-22616.
2. Christoph Rader. Chemically programmed antibodies. Trends Biotechnol. 2014, 32(4): 186–197.